Scynexis names Sanjay Subramanian as CFO, replacing retiring Ivor Macleod

Scynexis, Inc. announced on September 10, 2026 the appointment of Sanjay Subramanian, MBA, as Chief Financial Officer, effective September 9, 2026. SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, announced the appointment effective September 9, 2026.¹

The company also disclosed the retirement of Ivor Macleod from the CFO role, effective the same date. Macleod notified the company of his intent to retire and ceased serving as Chief Financial Officer, principal financial officer and principal accounting officer effective September 9, 2026.¹ He will remain with the company through October 9, 2026 to support a smooth transition, after which his employment will end.¹ CEO David Angulo said since joining SCYNEXIS in 2022, Ivor has played an important role in strengthening the company's financial position and supporting its strategic evolution.¹

Under his employment agreement, Subramanian will receive an annual base salary of $500,000, a one-time sign-on bonus of $20,000, a discretionary annual performance bonus of up to 40% of his base salary, and a stock option to purchase 100,000 shares of SCYNEXIS common stock at an exercise price equal to the closing price on the date of grant, vesting over four years.¹ The option was granted on September 9, 2026 at an exercise price of $4.91 per share, with a ten-year term, one-fourth vesting after one year and the remainder vesting monthly over the following 36 months.¹

The agreement also includes severance terms: nine months base salary, accelerated equity vesting and COBRA benefits if terminated without cause outside a change-of-control window, rising to 18 months of each if the termination occurs within 12 months of a change of control.¹

Before joining Scynexis, Subramanian served as Chief Financial Officer and Head of Business Development at Inozyme Pharma, Inc., where he led finance, investor relations, legal, and business development activities and played a key role in Inozyme's acquisition by BioMarin Pharmaceutical Inc.¹ He previously served as Chief Financial Officer and Head of Corporate Development at Ocugen, Inc., and earlier held finance leadership positions at Aralez Pharmaceuticals, Bausch Health Companies, and General Motors.¹